Date: Wednesday, June 6, 2018
Time: 1:45 PM–2:45 PM EST
Duration: 1 hour
Room: 210C, Level 2
While machine learning and artificial intelligence have had a deep impact in solving complex global problems over the past several years, there has been a slow adoption and implementation of these technologies for use in drug discovery R&D. AI-based technologies and platforms in the life sciences are still in their infancy, but this will be the way of the future for generating drugs and diagnostics.
In this panel discussion, we bring together leaders in machine learning and artificial intelligence in drug discovery and development to delve into the opportunities, capabilities, future trends and challenges of using AI to speed up drug discovery, decrease failure rates in drug trials, and create more affordable and better treatments for patients.
Moderator: Richard M. Soll, Senior Advisor, Strategic Initiatives & Head of Cambridge, MA. Office, WuXi AppTec
- Atul Butte, Priscilla Chan and Mark Zuckerberg Distinguished Professor; Director, Institute for Computational Health Sciences, UCSF
- Gini Deshpande, CEO and Founder, Numedii
- Vijay Pande, Henry Dreyfus Professor of Chemistry, Structural Biology and Computer Science, Director of Stanford Program in Biophysics and the Folding@home Distributed Computing project; and general partner at Andreessen Horowitz
- Dr. Amit Mehta, Associate Director in Business Development at Genentech. He focuses on sourcing and in-licensing opportunities in the areas of neuroscience, ophthalmology, personalized healthcare and advanced analytics